Distortions to national drug policy caused by lawsuits in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | https://www.revistas.usp.br/rsp/article/view/32216 |
Resumo: | OBJECTIVE: To describe how lawsuits, which demand the supply of drugs, impact on elements of the national drug policy. METHODS: This is a desk-based study using qualitative and quantitative methods. All legal proceedings brought by citizens against the Municipal Secretary of State of Sao Paulo, relating to the supply of drugs in 2005 were analyzed. A standardized form was used to collect data, with a view to carrying out an exploratory analysis. RESULTS: A total of 170 cases relating to the supply of drugs were brought against the Municipal Secretary of State. The National Health System (SUS) was the source for 59% of the prescriptions: 26% from the municipal level, 33% from other levels. Cancer and diabetes were the diseases most commonly involved (59%). About 62% of drugs requested are on the lists of SUS services. Total expenditure was R$876,000 (Brazilian Reais), covering only non-selected items (i.e. those which are not included in the Municipal Register of Essential Medicines), 73% of which could be substituted. Of the total expenditure, 75% was spent on purchasing anticancer drugs, for which further clinical trials are required to prove their effectiveness. Two of these medicines were not registered in Brazil. CONCLUSIONS: The majority of demands for drugs that have led to legal proceedings could be avoided if two SUS directives were followed, namely the organization of oncology services and the observance of reporting on essential medicines. Failure to do so causes a breakdown in the National Drug Policy, in equality of access and in the rational use of drugs within the National Health System. |
id |
USP-23_1570b5fdfa8916f189da24b5db8bafc3 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/32216 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Distortions to national drug policy caused by lawsuits in Brazil Distorções causadas pelas ações judiciais à política de medicamentos no Brasil Política Nacional de MedicamentosPolítica Nacional de Assistência FarmacêuticaSistema Único de SaúdeDecisões judiciaisNational Drug PolicyNational Policy on Pharmaceutical CareUnified Health SystemLegal Decisions OBJECTIVE: To describe how lawsuits, which demand the supply of drugs, impact on elements of the national drug policy. METHODS: This is a desk-based study using qualitative and quantitative methods. All legal proceedings brought by citizens against the Municipal Secretary of State of Sao Paulo, relating to the supply of drugs in 2005 were analyzed. A standardized form was used to collect data, with a view to carrying out an exploratory analysis. RESULTS: A total of 170 cases relating to the supply of drugs were brought against the Municipal Secretary of State. The National Health System (SUS) was the source for 59% of the prescriptions: 26% from the municipal level, 33% from other levels. Cancer and diabetes were the diseases most commonly involved (59%). About 62% of drugs requested are on the lists of SUS services. Total expenditure was R$876,000 (Brazilian Reais), covering only non-selected items (i.e. those which are not included in the Municipal Register of Essential Medicines), 73% of which could be substituted. Of the total expenditure, 75% was spent on purchasing anticancer drugs, for which further clinical trials are required to prove their effectiveness. Two of these medicines were not registered in Brazil. CONCLUSIONS: The majority of demands for drugs that have led to legal proceedings could be avoided if two SUS directives were followed, namely the organization of oncology services and the observance of reporting on essential medicines. Failure to do so causes a breakdown in the National Drug Policy, in equality of access and in the rational use of drugs within the National Health System. OBJETIVO: Descrever os efeitos das ações judiciais que requerem o fornecimento de medicamentos, em relação a aspectos da política nacional de medicamentos. MÉTODOS: Pesquisa documental, com abordagem metodológica quali-quantitativa. Foram analisados todos os processos movidos por cidadãos contra a Secretaria Municipal de Saúde de São Paulo, referentes ao fornecimento de medicamentos, durante o ano de 2005. Utilizou-se formulário padronizado para a coleta de dados, realizando-se uma análise exploratória. RESULTADOS: Foram impetradas 170 ações contra a Secretaria requerendo o fornecimento de medicamentos. Os serviços do Sistema Único de Saúde originaram 59% das prescrições (26% municipais e 33% os demais). Câncer e diabetes foram as doenças mais referidas (59%). Faziam parte de listas de serviços 62% dos medicamentos solicitados itens solicitados. O gasto total foi de R$876 mil, efetuado somente para itens não selecionados (que não fazem parte da Relação Municipal de Medicamentos Essenciais), 73% dos quais poderiam ser substituídos. Do gasto total, 75% foram destinados à aquisição de antineoplásicos, cuja comprovação de eficácia necessita de mais ensaios clínicos. Dois desses medicamentos não estavam registrados no Brasil. CONCLUSÕES: A maioria das demandas por medicamentos geradas por ações judiciais poderia ser evitada se fossem consideradas as diretrizes do Sistema Único de Saúde, a organização do atendimento em oncologia e a observância das relações de medicamentos essenciais. A falta dessa observância compromete a Política Nacional de Medicamentos, a eqüidade no acesso e o uso racional de medicamentos no Sistema Único de Saúde. Universidade de São Paulo. Faculdade de Saúde Pública2007-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://www.revistas.usp.br/rsp/article/view/3221610.1590/S0034-89102007000200007Revista de Saúde Pública; Vol. 41 No. 2 (2007); 214-222 Revista de Saúde Pública; Vol. 41 Núm. 2 (2007); 214-222 Revista de Saúde Pública; v. 41 n. 2 (2007); 214-222 1518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPporenghttps://www.revistas.usp.br/rsp/article/view/32216/34330https://www.revistas.usp.br/rsp/article/view/32216/34331Copyright (c) 2017 Revista de Saúde Públicainfo:eu-repo/semantics/openAccessVieira, Fabiola SulpinoZucchi, Paola2012-07-09T00:30:58Zoai:revistas.usp.br:article/32216Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2012-07-09T00:30:58Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Distortions to national drug policy caused by lawsuits in Brazil Distorções causadas pelas ações judiciais à política de medicamentos no Brasil |
title |
Distortions to national drug policy caused by lawsuits in Brazil |
spellingShingle |
Distortions to national drug policy caused by lawsuits in Brazil Vieira, Fabiola Sulpino Política Nacional de Medicamentos Política Nacional de Assistência Farmacêutica Sistema Único de Saúde Decisões judiciais National Drug Policy National Policy on Pharmaceutical Care Unified Health System Legal Decisions |
title_short |
Distortions to national drug policy caused by lawsuits in Brazil |
title_full |
Distortions to national drug policy caused by lawsuits in Brazil |
title_fullStr |
Distortions to national drug policy caused by lawsuits in Brazil |
title_full_unstemmed |
Distortions to national drug policy caused by lawsuits in Brazil |
title_sort |
Distortions to national drug policy caused by lawsuits in Brazil |
author |
Vieira, Fabiola Sulpino |
author_facet |
Vieira, Fabiola Sulpino Zucchi, Paola |
author_role |
author |
author2 |
Zucchi, Paola |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Vieira, Fabiola Sulpino Zucchi, Paola |
dc.subject.por.fl_str_mv |
Política Nacional de Medicamentos Política Nacional de Assistência Farmacêutica Sistema Único de Saúde Decisões judiciais National Drug Policy National Policy on Pharmaceutical Care Unified Health System Legal Decisions |
topic |
Política Nacional de Medicamentos Política Nacional de Assistência Farmacêutica Sistema Único de Saúde Decisões judiciais National Drug Policy National Policy on Pharmaceutical Care Unified Health System Legal Decisions |
description |
OBJECTIVE: To describe how lawsuits, which demand the supply of drugs, impact on elements of the national drug policy. METHODS: This is a desk-based study using qualitative and quantitative methods. All legal proceedings brought by citizens against the Municipal Secretary of State of Sao Paulo, relating to the supply of drugs in 2005 were analyzed. A standardized form was used to collect data, with a view to carrying out an exploratory analysis. RESULTS: A total of 170 cases relating to the supply of drugs were brought against the Municipal Secretary of State. The National Health System (SUS) was the source for 59% of the prescriptions: 26% from the municipal level, 33% from other levels. Cancer and diabetes were the diseases most commonly involved (59%). About 62% of drugs requested are on the lists of SUS services. Total expenditure was R$876,000 (Brazilian Reais), covering only non-selected items (i.e. those which are not included in the Municipal Register of Essential Medicines), 73% of which could be substituted. Of the total expenditure, 75% was spent on purchasing anticancer drugs, for which further clinical trials are required to prove their effectiveness. Two of these medicines were not registered in Brazil. CONCLUSIONS: The majority of demands for drugs that have led to legal proceedings could be avoided if two SUS directives were followed, namely the organization of oncology services and the observance of reporting on essential medicines. Failure to do so causes a breakdown in the National Drug Policy, in equality of access and in the rational use of drugs within the National Health System. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/32216 10.1590/S0034-89102007000200007 |
url |
https://www.revistas.usp.br/rsp/article/view/32216 |
identifier_str_mv |
10.1590/S0034-89102007000200007 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/32216/34330 https://www.revistas.usp.br/rsp/article/view/32216/34331 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2017 Revista de Saúde Pública info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2017 Revista de Saúde Pública |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
dc.source.none.fl_str_mv |
Revista de Saúde Pública; Vol. 41 No. 2 (2007); 214-222 Revista de Saúde Pública; Vol. 41 Núm. 2 (2007); 214-222 Revista de Saúde Pública; v. 41 n. 2 (2007); 214-222 1518-8787 0034-8910 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1800221786044891136 |